Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (7204)	11/21/1999 1:57:00 PM
From: Andreas Helke	Read Replies (2) \| Respond to of 9719

Hi Vector1, I wonder what you expected and what you now see about MGI-114 results. I took your posting as a reason once again check the status of MGI Pharma (this is one of my bigger biotech investments). So far I see no compelling reason to abandon MGI Pharma now. If MGI-114 fails this will be very bad for the stock price but thanks to its other drugs MGI Pharma would easily survive such an event. As I currently see it MGI-114 is unfortunately one of those toxic drugs that should become less important when the biotech industry invents more non toxic cancer treatments. But it seems to be effective enough that it should have not much problems from lack of effectivity to get FDA approval. I don't yet know enough about the safety side of this drug. BTW what do you think about the recent stop of the Biogens Antova trials? I wonder why this serious setback to Biogens pipeline combined with the impending loss of orphan drug protection for Avonex in a few years did not do more damage to Biogens share price. I will probably sell half of my Biogen shares. Andreas